From Financial Modeling Prep: 2024-12-26 00:00:02

In preparation for its quarterly earnings release, Lifecore Biomedical, Inc. (NASDAQ: LFCR) is expected to report an EPS loss of $0.27 with projected revenue around $29.7 million. The company’s P/E ratio of 35.87 indicates the premium investors are willing to pay for its earnings. LFCR’s current ratio of 1.83 showcases a solid liquidity position to cover short-term liabilities.



Read more at Financial Modeling Prep:: Lifecore Biomedical, Inc. (NASDAQ: LFCR) Quarterly…